tiprankstipranks
Advertisement
Advertisement
NextCure initiates dose optimization portion of SIM0505 study
PremiumThe FlyNextCure initiates dose optimization portion of SIM0505 study
1M ago
NextCure granted Fast Track Designation for SIM0505 by FDA
Premium
The Fly
NextCure granted Fast Track Designation for SIM0505 by FDA
2M ago
NextCure trading resumes
Premium
The Fly
NextCure trading resumes
3M ago
NextCure Launches At-The-Market Stock Offering Program
PremiumCompany AnnouncementsNextCure Launches At-The-Market Stock Offering Program
6M ago
NextCure files to sell 2.52M shares of common stock for holders
Premium
The Fly
NextCure files to sell 2.52M shares of common stock for holders
6M ago
NextCure Raises $21.5M in Private Placement
Premium
Company Announcements
NextCure Raises $21.5M in Private Placement
7M ago
NextCure Advances Cancer Therapies Amid Financial Adjustments
PremiumCompany AnnouncementsNextCure Advances Cancer Therapies Amid Financial Adjustments
7M ago
NextCure reports Q3 EPS ($3.22), consensus ($3.98)
Premium
The Fly
NextCure reports Q3 EPS ($3.22), consensus ($3.98)
7M ago
NextCure’s Phase I Study of SIM0505: A Potential Breakthrough in Cancer Treatment
Premium
Company Announcements
NextCure’s Phase I Study of SIM0505: A Potential Breakthrough in Cancer Treatment
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100